Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:20:26 EDT Wed 13 May 2026
Enter Symbol
or Name
USA
CA



Q:AGEN - AGENUS INC - https://agenusbio.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AGEN - Q5.02.50·3.830.13.47+0.030.9575.81,8283,1183.41  3.58  3.397.34  2.7118:58:32May 1115 min RT 2¢

Recent Trades - Last 10 of 3118
Time ETExPriceChangeVolume
18:58:32Q3.530.0950
17:55:55Q3.470.031
17:50:44Q3.45170.01177
16:10:04Q3.470.031
16:10:04Q3.470.031
16:10:03Q3.470.031
16:10:03Q3.470.031
16:04:50Q3.470.031
16:04:30Q3.470.031
16:04:17Q3.470.031

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-11 08:45U:AGENNews ReleaseAgenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
2026-05-04 16:30U:AGENNews ReleaseAgenus to Provide First Quarter 2026 Financial Report and Corporate Update
2026-04-21 10:00U:AGENNews ReleaseAgenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
2026-04-21 08:00U:AGENNews ReleaseAgenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
2026-04-17 16:43U:AGENNews ReleaseAgenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
2026-04-03 07:30U:AGENNews ReleaseAgenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
2026-04-01 07:30U:AGENNews ReleaseAgenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
2026-03-26 16:52U:AGENNews ReleaseAgenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
2026-03-17 16:40U:AGENNews ReleaseAgenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
2026-03-16 07:30U:AGENNews ReleaseAgenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
2026-03-10 07:30U:AGENNews ReleaseAgenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
2026-03-04 16:30U:AGENNews ReleaseAgenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
2026-02-19 15:15U:AGENNews ReleaseAgenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
2026-02-09 13:00U:AGENNews ReleaseAgenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
2026-01-21 07:30U:AGENNews ReleaseAgenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
2026-01-20 18:24U:AGENNews ReleaseAgenus to Host First 2026 Stakeholder Webcast
2026-01-15 07:01U:AGENNews ReleaseAgenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
2026-01-12 07:30U:AGENNews ReleaseFrance Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
2025-12-23 08:05U:AGENNews ReleaseAgenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
2025-12-12 10:31U:AGENNews ReleaseGI Cancer Immunotherapy Breakthroughs Signal New Treatment Era